Form 4: Fulgent Genetics CFO Sells Shares for Tax Obligations

Fulgent Genetics' CFO and Treasurer, Paul Kim, disposed of 1,166 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT), disposed of 1,166 shares of common stock.
• The transaction occurred on November 26, 2025, at a price of $30.15 per share.
• The shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on February 26, 2024.
• Following this transaction, Paul Kim beneficially owns 332,281 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (tax withholding) which is neutral in sentiment. It reflects the vesting of previously granted equity, which is a positive for the executive, but the sale itself is a neutral, administrative event.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of previously granted restricted stock units, which is a positive for the executive's compensation.

Negatives

• The disposal of shares, even for tax purposes, reduces the direct ownership stake of the CFO, though this is a common and expected practice.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider transaction related to executive compensation and tax obligations, which is a common occurrence across all industries for publicly traded companies when restricted stock units vest. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This transaction is a standard practice for executives receiving equity compensation in the form of restricted stock units. It aligns with typical industry practices where a portion of vested shares is withheld to cover tax liabilities. No specific comparable companies or projects are mentioned in the filing to allow for a detailed comparative assessment.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• No related party transactions are disclosed beyond the executive's compensation-related stock vesting and tax withholding.

Stakeholder Impact

• The direct impact on shareholders is minimal as this is a routine, small-scale transaction for tax purposes.
• Employees are not directly impacted by this specific filing.
• Customers, suppliers, and creditors are not impacted by this insider transaction report.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the reporting of a past transaction.

Key Dates

Keywords

Fulgent Genetics, FLGT, Paul Kim, CFO, Treasurer, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting